Type 2 Diabetes Update: Semaglutide and Linagliptin as Basal Insulin Alternatives
Cardiovascular comorbidities and risk reduction play a major new role in pharmacologic therapy for type 2 diabetes, with sodium-glucose transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists now recommended as part of the glucose-lowering regimen for patients who have established atherosclerotic cardiovascular disease (ASCVD) or indicators of high-risk, chronic kidney disease (CKD) or heart failure (HF).
Source: Caring for the Ages - Category: Health Management Authors: Christine Kilgore Source Type: news
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Diabetes | Diabetes Type 2 | Endocrinology | Health Management | Heart | Heart Failure | Insulin | SGLT2 Inhibitors | Sodium | Urology & Nephrology